Company
Headquarters: Hangzhou, China
CEO: Mr. Lieming Ding
CN¥20.57 Billion
CNY as of Jan. 1, 2026
US$2.93 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. Betta Pharmaceuticals Co., Ltd. was founded in 2003 and is headquartered in Hangzhou, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥3.26 B |
| EBITDA | CN¥516.0 M |
| Gross Profit TTM | CN¥2.57 B |
| Profit Margin | 9.29% |
| Operating Margin | 20.21% |
| Quarterly Revenue Growth | 16.80% |
Betta Pharmaceuticals Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300558